ProQR to Participate in 8th Annual Evercore Healthcare Conference

Core Insights - ProQR Therapeutics is participating in the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 8:20 am ET, indicating its active engagement in the healthcare investment community [1] Company Overview - ProQR Therapeutics is focused on developing transformative RNA therapies using its proprietary Axiomer technology platform, which utilizes ADAR-mediated RNA editing to create targeted medicines for various diseases [3][4] - The Axiomer platform allows for specific single nucleotide changes in RNA, potentially reversing mutations or modulating protein expression, which could lead to new treatments for both rare and common diseases [3][4] Technology Details - Axiomer employs Editing Oligonucleotides (EONs) to facilitate precise edits in RNA, converting Adenosine (A) to Inosine (I), which is then translated as Guanosine (G), thereby correcting disease-causing mutations [3] - The technology aims to leverage the body's own molecular machinery to develop a new class of medicines, addressing unmet medical needs [4]